Research programme: non-nucleoside reverse transcriptase inhibitors - GlaxoSmithKline

Drug Profile

Research programme: non-nucleoside reverse transcriptase inhibitors - GlaxoSmithKline

Alternative Names: 678248; GSK 3968A; GSK3986A; GW 3011; GW 4511; GW 4751; GW 8248; GW 8248X; GW 8635

Latest Information Update: 19 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Amides; Benzophenones
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 21 Aug 2008 Pharmacodynamics and pharmacokinetics data from a preclinical trial in HIV infections presented at the 236th American Chemical Society National Meeting (236th-ACS-2008)
  • 28 Jul 2003 Data presented at the 2nd IAS Conference on HIV Pathogenesis and Treatment (IAS-2003) have been added to the Viral infections pharmacodynamics section ,
  • 06 May 2003 Data presented at the 16th International Conference on Antiviral Research (ICAR-2003) have been added to the Viral infections therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top